The Effects of Mesenchymal Stem Cells on Antimelanoma Immunity Depend on the Timing of Their Administration by Dragana Miloradovic, Dragica Miloradovic, Bojana Simovic Markovic, Aleksandar Acovic, Carl Randall Harrell, Valentin Djonov, Nebojsa Arsenijevic, Vladislav Volarevic

“…Significantly higher plasma levels of antitumorigenic cytokines (TNF-α and IFN-γ), remarkably lower plasma levels of immunosuppressive cytokines (TGF-β and IL-10), and a significantly higher number of tumor-infiltrating, IFN-γ-producing, FasL- and granzyme B-expressing NK cells, IL-17-producing CD4+Th17 cells, IFN-γ- and TNF-α-producing CD4+Th1 cells, and CD8+cytotoxic T lymphocytes (CTLs) were observed in B16F10+MSC1d-treated mice. …”
Get full text

Arginase-1-specific T cells target and modulate tumor-associated macrophages by Mads Hald Andersen, Inés Lecoq, Ayako Wakatsuki Pedersen, Evelina Martinenaite, Shamaila Munir Ahmad, Maria Perez-Penco, Lucia Lara de la Torre, Marion Chapellier, Lars Rønn Olsen, Mia Aaboe-Jørgensen, Hannah Jorinde Glöckner, Anne Mette Askehøj Rømer

“…The effect of Arg1-derived peptide IMV on TAMs in vivo was assessed by multiplex gene analysis of F4/80+cells.Results We show that Arg1-based IMV-mediated tumor control was linked to a decrease in multiple immunosuppressive pathways in the TAM population of the treated animals. …”
Get full text

SARS-CoV-2 infections in pediatric and young adult recipients of chimeric antigen receptor T-cell therapy: an international registry report by Hongyan Liu, Colleen Callahan, Shannon L Maude, Kevin Owen McNerney, Rebecca M Richards, Paibel Aguayo-Hiraldo, Friso G Calkoen, Julie-An Talano, Amy Moskop, Adriana Balduzzi, Jennifer Krajewski, Hema Dave, Anant Vatsayan, Yimei Li, Kara Lynn Davis

“…Patients undergoing chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory B-cell malignancies are uniquely immunosuppressed due to CAR T-mediated B-cell aplasia (BCA). …”
Get full text

4-1BB agonist targeted to fibroblast activation protein α synergizes with radiotherapy to treat murine breast tumor models by Ignacio Melero, Alvaro Teijeira, Christian Klein, Maria E Rodriguez-Ruiz, Christina Claus, Pablo Umana, Tamara Tanos, Carlos E De Andrea, Carlos Luri-Rey, Paloma Sanchez-Mateos, Leticia Fernández-Rubio, María Collantes, Irantzu Serrano-Mendioroz, Celia Barrio-Alonso, Antonio Rullan, Jon Ander Simon, Eneko Garate-Soraluze, Claudia del Pilar Herrero

“…Background Ionizing radiation (IR) is a double-edged sword for immunotherapy as it may have both immunosuppressive and immunostimulatory effects. The biological effects of IR on the tumor microenvironment (TME) are a key factor for this balance. …”
Get full text

PD-L1/TLR7 dual-targeting nanobody-drug conjugate mediates potent tumor regression via elevating tumor immunogenicity in a host-expressed PD-L1 bias-dependent way by Wei Huang, Ji Zhou, Jia Li, Yakun Wan, Chao Hu, Meng Liu, Pan Xu, Feng Tang, Jianhua Sun, Xiaolu Yu, Yiru Long, Binfan Chen, Yongliang Tong, Mengwen Shan, Xiaomin Jia, Henglei Lu, Runqiu Chen, Jin Ren, Guangyi Jin, Likun Gong

“…The dynamics of the in vivo behaviors of NDCs were assessed based on multiorgan changes in PD-L1 levels.Results The screened PD-L1 nanobodies were characterized as tumor-targeting and alleviated T-cell immunosuppression. The TLR7 agonists induced broad innate immune responses and intratumoral PD-L1 expression on antigen-presenting cells (APCs), and its antitumor effect was dependent on intratumoral delivery. …”
Get full text

Exploration of rituximab treatment strategies for membranous nephropathy adapted to the Chinese healthcare environment by Xiaolong Wang, Xueying Cao, Jie Wu, Shuang Liang, Jian Yang, Hong Wang

“…We collected clinical data from these patients and categorized them into three groups on the basis of their RTX treatment background: the combined glucocorticoids (GCs) and/or immunosuppressants (IMS) and RTX monotherapy treatment groups, the initial and non-initial treatment groups, and the standard RTX and non-standard RTX treatment groups. …”
Get full text

Cancer cells avoid ferroptosis induced by immune cells via fatty acid binding proteins by Maria Angelica Freitas-Cortez, Fatemeh Masrorpour, Hong Jiang, Iqbal Mahmud, Yue Lu, Ailing Huang, Lisa K. Duong, Qi Wang, Tiffany A. Voss, Claudia S. Kettlun Leyton, Bo Wei, Wai-Kin Chan, Kevin Lin, Jie Zhang, Efrosini Tsouko, Shonik Ganjoo, Hampartsoum B. Barsoumian, Thomas S. Riad, Yun Hu, Carola Leuschner, Nahum Puebla-Osorio, Jing Wang, Jian Hu, Michael A. Davies, Vinay K. Puduvalli, Cyrielle Billon, Thomas P. Burris, Philip L. Lorenzi, Boyi Gan, James W. Welsh

“…Abstract Background Cancer creates an immunosuppressive environment that hampers immune responses, allowing tumors to grow and resist therapy. …”
Get full text

Disrupting EDEM3‐induced M2‐like macrophage trafficking by glucose restriction overcomes resistance to PD‐1/PD‐L1 blockade by Shaoyong Peng, Minshan Wu, Qian Yan, Gaopo Xu, Yumo Xie, Guannan Tang, Jinxin Lin, Zixu Yuan, Xiaoxia Liang, Ze Yuan, Jingrong Weng, Liangliang Bai, Xiaolin Wang, Huichuan Yu, Meijin Huang, Yanxin Luo, Xiaoxia Liu

“…Abstract Background Immunotherapy is beneficial for some colorectal cancer (CRC) patients, but immunosuppressive networks limit its effectiveness. Cancer‐associatedfibroblasts (CAFs) are significant in immune escape and resistance toimmunotherapy, emphasizing the urgent need for new treatment strategies. …”
Get full text

A Predictive Model for Pulmonary Aspergillosis in ICU Patients: A Multicenter Retrospective Cohort Study by Li Y, Ren X, Wang Q, Shen S, Li Y, Qian X, Tang Y, Jia J, Zhang H, Ding J, Song Y, Zhang S, Wang S, Xu Y, Jiang Y, He X, Dai M, Zhong L, Xiong Y, Pan Y, Wang M, Shao H, Cai H, Huang L, Wang H

“…The risk prediction model for IPA, incorporating microbiological characteristics, identified six independent risk factors, namely age, immunosuppression, chronic kidney disease, connective tissue disease, liver failure, and cytomegalovirus positivity. …”
Get full text

Dynamic Challenges of Active Tuberculosis: Prevalence and Risk Factors of Co-Infection in Clinical and Microbiological Characteristics at King Abdulaziz University Hospital, Jeddah... by Mokhtar JA, Attallah DM, Jiman-Fatani AA, Al-Rabia MW, Alqarni MA, Saleh BH, Amboon MM, Altorki TA, Alkuwaity KK, Abujamel T, Kaki R, Albarakati TN, Daghistani H, Ismail MA, Alharbi O, Abu ITM, Alfadil A, Ibrahem K, Mufrrih M, Sait AM

“…Immunocompromising conditions, including comorbidities, malignancies, and the use of immunosuppressive agents, are major risk factors for active TB (ATB).Objective: To analyze clinical factors and estimate mortality in TB and drug-resistant cases.Methods: This retrospective study analyzed medical records of 12,494 patients at KAUH (2019– 2021), identifying 131 confirmed TB cases with comprehensive data on demographics, clinical features, comorbidities, diagnostics, and outcomes. …”
Get full text

Enhancement of anti‐sarcoma immunity by NK cells engineered with mRNA for expression of a EphA2‐targeted CAR by Pui Yeng Lam, Natacha Omer, Josh K. M. Wong, Cui Tu, Louisa Alim, Gustavo R. Rossi, Maria Victorova, Hannah Tompkins, Cheng‐Yu Lin, Ahmed M. Mehdi, Amos Choo, Melissa R. Elliott, Elaina Coleborn, Jane Sun, Timothy Mercer, Orazio Vittorio, Lachlan J. Dobson, Alexander D. McLellan, Andrew Brooks, Zewen Kelvin Tuong, Seth W. Cheetham, Wayne Nicholls, Fernando Souza‐Fonseca‐Guimaraes

“…However, CAR‐T cells have faced significant challenges and limited success in treating solid tumours due to issues such as poor tumour infiltration, immunosuppressive tumour microenvironments and off‐target effects. …”
Get full text

Contextual Vulnerability Should Guide Fair Subject Selection in Xenotransplantation Clinical Trials by Gianna Strand

“…Multi-center research studies have found that moderate non-adherence to immunosuppression regimens is not directly associated with poor kidney transplant outcomes.…”
Get full text